Stocktoria
Rallybio Corp RLYB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-07-29
Rallybio Corp financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $858,000 | $636,000 | — | — | — |
| R&D expense | $19.6M | $41.5M | $53.5M | $40.7M | $26.9M |
| Operating income | -$33.1M | -$60.5M | -$78.9M | -$67.9M | -$45.6M |
| Interest expense | — | — | — | $0 | $10,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$9.0M | -$57.8M | -$74.6M | -$66.7M | -$47.0M |
| EPS (diluted) | $-1.59 | $-10.61 | $-1.84 | $-2.09 | $-1.84 |
| Operating cash flow | -$29.8M | -$49.3M | -$60.3M | -$57.3M | -$45.5M |
| Free cash flow | — | -$49.3M | -$60.3M | -$57.3M | -$45.9M |
| Cash & equivalents | $31.4M | $13.9M | $24.5M | $57.0M | $175.3M |
| Total assets | $62.3M | $68.1M | $115.6M | $180.4M | $182.2M |
| Total liabilities | $4.3M | $6.5M | $9.4M | $11.1M | $6.6M |
| Shareholders' equity | $58.0M | $61.7M | $106.2M | $169.3M | $175.6M |
Source: SEC EDGAR filings · CIK 0001739410 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.